Resona Asset Management Co. Ltd. Grows Holdings in HCA Healthcare, Inc. $HCA

Resona Asset Management Co. Ltd. increased its position in HCA Healthcare, Inc. (NYSE:HCA) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,038 shares of the company’s stock after buying an additional 1,085 shares during the period. Resona Asset Management Co. Ltd.’s holdings in HCA Healthcare were worth $24,113,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Atlantic Union Bankshares Corp purchased a new stake in shares of HCA Healthcare in the second quarter valued at $48,000. Moors & Cabot Inc. increased its stake in shares of HCA Healthcare by 4.4% during the 2nd quarter. Moors & Cabot Inc. now owns 896 shares of the company’s stock valued at $343,000 after acquiring an additional 38 shares during the last quarter. Crestwood Advisors Group LLC acquired a new stake in shares of HCA Healthcare in the second quarter worth approximately $278,000. Cassaday & Co Wealth Management LLC acquired a new position in HCA Healthcare during the second quarter worth approximately $270,000. Finally, Huntington National Bank grew its stake in shares of HCA Healthcare by 6.8% during the 2nd quarter. Huntington National Bank now owns 4,998 shares of the company’s stock valued at $1,915,000 after buying an additional 318 shares during the period. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

NYSE:HCA opened at $471.00 on Friday. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $478.19. The stock has a market cap of $107.48 billion, a P/E ratio of 18.21, a PEG ratio of 1.38 and a beta of 1.41. The firm has a 50-day moving average of $426.28 and a two-hundred day moving average of $390.24.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The firm had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. During the same quarter in the prior year, the business posted $4.90 earnings per share. HCA Healthcare’s revenue for the quarter was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, equities analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s dividend payout ratio (DPR) is currently 11.13%.

Insider Transactions at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares in the company, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president directly owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their target price on HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a report on Monday, August 4th. Wells Fargo & Company boosted their target price on HCA Healthcare from $375.00 to $412.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 7th. Morgan Stanley set a $425.00 price target on shares of HCA Healthcare in a research report on Monday, October 27th. Barclays lifted their target price on shares of HCA Healthcare from $445.00 to $494.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Finally, TD Cowen raised their price objective on HCA Healthcare from $380.00 to $490.00 and gave the company a “buy” rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, HCA Healthcare has an average rating of “Moderate Buy” and a consensus target price of $473.53.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.